Bellevue Group Portfolio holdings
Bellevue Group is a Swiss asset manager that focuses on healthcare investing, small and mid-cap companies and other growth strategies. Martin Bisang and four other founders started it in 1993, and through its subsidiary Bank am Bellevue it first became a major name in brokerage and block trading on the Swiss market. It sold that bank to Luxembourg's KBL Group in 2019, dropping its private client business and becoming a pure asset manager. In 2016 it bought the German asset manager StarCapital to build its presence in Germany, and in 2023 it launched Bellevue Obesity Solutions, a global equity fund.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
AGN
Allergan plc
AGN
|
+$8.09M |
| 2 |
Stryker
SYK
|
+$5.81M |
| 3 |
AMSG
Amsurg Corp
AMSG
|
+$5.72M |
| 4 |
ABMD
Abiomed Inc
ABMD
|
+$5.69M |
| 5 |
Hologic
HOLX
|
+$5.45M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Gilead Sciences
GILD
|
+$6.82M |
| 2 |
Becton Dickinson
BDX
|
+$6.76M |
| 3 |
Biogen
BIIB
|
+$5.81M |
| 4 |
Supernus Pharmaceuticals
SUPN
|
+$4.91M |
| 5 |
INSY
Insys Therapeutics, Inc.
INSY
|
+$4.49M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 97.25% |
| 2 | Miscellaneous | 2.16% |
| 3 | Financials | 0.6% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
1
Medtronic
MDT
$126B
| $24.5M | 4.61% |
282,500
+6,000
| +2% | +$485K |
2016 Q1
1 quarter
|
|
|
2
Stryker
SYK
$117B
| $21.2M | 3.99% |
177,000
+52,000
| +42% | +$5.81M |
2016 Q1
1 quarter
|
|
|
CELG
3
DELISTED
Celgene Corp
CELG
| $19.3M | 3.64% |
196,050
-14,500
| -7% | -$1.5M |
2016 Q1
1 quarter
|
|
4
Abbott
ABT
$189B
| $15M | 2.82% |
381,500
| – | – |
2016 Q1
1 quarter
|
|
5
Cardinal Health
CAH
$58.8B
| $14.7M | 2.77% |
188,780
+29,150
| +18% | +$2.32M |
2016 Q1
1 quarter
|
|
6
UnitedHealth
UNH
$357B
| $14M | 2.64% |
99,200
+6,200
| +7% | +$827K |
2016 Q1
1 quarter
|
|
|
7
Biogen
BIIB
$36.9B
| $13.2M | 2.48% |
54,500
-22,040
| -29% | -$5.81M |
2016 Q1
1 quarter
|
|
|
8
Gilead Sciences
GILD
$211B
| $13.1M | 2.46% |
156,500
-76,800
| -33% | -$6.82M |
2016 Q1
1 quarter
|
|
9
Illumina
ILMN
$34.5B
| $12.9M | 2.42% |
94,139
-52
| -0.1% | -$7.39K |
2016 Q1
1 quarter
|
|
10
Amgen
AMGN
$253B
| $12.7M | 2.39% |
83,500
-19,500
| -19% | -$3.03M |
2016 Q1
1 quarter
|
|
11
Boston Scientific
BSX
$63.8B
| $11.7M | 2.2% |
500,000
| – | – |
2016 Q1
1 quarter
|
|
12
Teva Pharmaceutical Industries Limited
TEVA
$48B
| $11.5M | 2.17% |
229,190
+33,900
| +17% | +$1.8M |
2016 Q1
1 quarter
|
|
13
Jazz Pharmaceuticals
JAZZ
$14.1B
| $10.6M | 2% |
75,300
+12,800
| +20% | +$1.89M |
2016 Q1
1 quarter
|
|
14
Regeneron Pharmaceuticals
REGN
$100B
| $10.5M | 1.97% |
30,000
-2,400
| -7% | -$924K |
2016 Q1
1 quarter
|
|
15
Zimmer Biomet
ZBH
$18.5B
| $10.4M | 1.95% |
88,786
| – | – |
2016 Q1
1 quarter
|
|
|
16
Becton Dickinson
BDX
$54.3B
| $10M | 1.88% |
60,475
-42,256
| -41% | -$6.76M |
2016 Q1
1 quarter
|
|
17
DELISTED
Altamira Therapeutics Ltd
CYTO
| $9.09M | 1.71% |
27
| – | – |
2016 Q1
1 quarter
|
|
18
Ligand Pharmaceuticals
LGND
$6.2B
| $8.47M | 1.59% |
113,861
-17,312
| -13% | -$1.28M |
2016 Q1
1 quarter
|
|
19
Centene
CNC
$32.7B
| $8.38M | 1.58% |
234,760
+23,000
| +11% | +$722K |
2016 Q1
1 quarter
|
|
|
20
DELISTED
Hologic
HOLX
| $8.24M | 1.55% |
238,300
+157,300
| +194% | +$5.45M |
2016 Q1
1 quarter
|
|
|
AGN
21
DELISTED
Allergan plc
AGN
| $8.11M | 1.53% |
+35,100
| New | +$8.09M |
2016 Q2
0 quarters
|
|
22
Intuitive Surgical
ISRG
$157B
| $7.94M | 1.49% |
108,000
-9,000
| -8% | -$633K |
2016 Q1
1 quarter
|
|
23
CVS Health
CVS
$113B
| $7.64M | 1.44% |
79,800
-6,400
| -7% | -$638K |
2016 Q1
1 quarter
|
|
24
Baxter International
BAX
$12.3B
| $7.51M | 1.41% |
166,000
+36,000
| +28% | +$1.58M |
2016 Q1
1 quarter
|
|
25
Incyte
INCY
$24.3B
| $7.28M | 1.37% |
91,000
| – | – |
2016 Q1
1 quarter
|
|
Similar funds
Bellevue Group's Q2 2016 Portfolio in Review
As of Q2 2016, Bellevue Group held 139 positions worth $531M, down 3.6% from $551M the previous quarter. Its ten largest holdings account for 30% of the portfolio.
Bellevue Group withdrew a net $36.7M in Q2 2016, closing 15 positions and reducing 40 holdings. Its most notable exit was Insys Therapeutics, Inc., an estimated $4.49M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 97% of assets, up from 97% a quarter earlier, followed by Miscellaneous and Financials.
Against the trend, Bellevue Group opened a new position in Allergan plc worth $8.11M.
- Bellevue Group's largest Q2 2016 buy was Allergan plc: 35,100 shares worth $8.11M.
- Bellevue Group added most to Stryker in Q2 2016, an estimated $5.81M increase.
- Bellevue Group's biggest Q2 2016 reduction was Gilead Sciences, cutting an estimated $6.82M.
- Bellevue Group fully exited Insys Therapeutics, Inc. in Q2 2016, selling an estimated $4.49M.
- Bellevue Group's ten largest holdings make up 30% of its $531M portfolio in Q2 2016.
- Bellevue Group opened 9 new positions and closed 15 in Q2 2016.
- Bellevue Group's portfolio value fell 3.6% quarter-over-quarter to $531M.
Based on Bellevue Group's 13F filing for Q2 2016, filed 12 Aug 2016.